









Markets
/
Stocks
/
nasdaq-ormp
/

Oramed Pharmaceuticals Inc

ORMP

3.410USD

+0.170+5.25%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

139.26MMarket Cap

3.25P/E TTM



Oramed Pharmaceuticals Inc

3.410

+0.170+5.25%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Oramed Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Oramed Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 197 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 3.25.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Oramed Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

197 / 392

Overall Ranking

380 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Oramed Pharmaceuticals Inc Highlights

StrengthsRisks

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is 3.25, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.24M shares, decreasing 7.11% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 148.90K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

3.250

Target Price

+36.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Oramed Pharmaceuticals Inc is 7.58, ranking 97 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

9.06

Change

-1.48



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Oramed Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Oramed Pharmaceuticals Inc is 7.75, ranking 83 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 3.25, which is 704.47% below the recent high of 26.12 and 530.32% above the recent low of -13.97.

Score

Industry at a Glance

Previous score

7.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 197/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Oramed Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 8.05. The average price target is 3.25, with a high of 3.25 and a low of 3.25.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Oramed Pharmaceuticals Inc is 6.96, ranking 131 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.72 and the support level at 3.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.69

Change

0.27

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Neutral

RSI(14)

56.839

Neutral

STOCH(KDJ)(9,3,3)

36.077

Neutral

ATR(14)

0.186

Low Volatility

CCI(14)

-90.651

Neutral

Williams %R

55.814

Sell

TRIX(12,20)

0.647

Sell

StochRSI(14)

74.136

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.376

Buy

MA10

3.421

Sell

MA20

3.397

Buy

MA50

2.999

Buy

MA100

2.633

Buy

MA200

2.411

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Oramed Pharmaceuticals Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.21%, representing a quarter-over-quarter increase of 27.12%. The largest institutional shareholder is James Simons, holding a total of 148.90K shares, representing 0.37% of shares outstanding, with 7.25% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BML Capital Management LLC

3.17M

+2.72%

Kidron (Nadav)

2.62M

+27.12%

Shapiro (Benjamin)

1.97M

+1.73%

Murchinson Ltd.

1.75M

Hexter Joshua

812.17K

+18.51%

Kidron (Miriam)

777.83K

-0.45%

Boothbay Fund Management, LLC

845.39K

Gabay (Avraham)

349.22K

+128.24%

Rathbones Investment Management Limited

233.02K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Oramed Pharmaceuticals Inc is 3.61, ranking 133 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.